Pyxis Oncology (PYXS) Q2 2026 earnings summary

Executive summary

• MICVO advanced in Phase 1 monotherapy and combination studies for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), with promising efficacy and tolerability in preliminary data and key updates expected in Fall and Q4 2026.

• Completed private placement financing in July 2026, raising $50 million upfront with potential for up to $114 million in gross proceeds, extending cash runway into Q2 2027.

• Focused on generating clinical evidence for MICVO's potential in HNSCC, regardless of HPV status or prior therapy.

• Positive preliminary results from both monotherapy and combination trials with KEYTRUDA®; dose capping strategies implemented to improve safety profile.

Financial highlights

• Net loss of $25.3 million for Q2 2026, compared to $18.4 million in Q2 2025; net loss of $48.6 million for the six months ended June 30, 2026, up from $39.5 million year-over-year.

• No revenue recognized in Q2 2026; prior year included $2.8 million milestone revenue from Simcere out-licensing.

• Research and development expenses were $16.1 million in Q2 2026, down from $17.1 million year-over-year; general and administrative expenses increased to $9.9 million, mainly due to higher severance and stock-based compensation.

• Cash, cash equivalents, and marketable debt securities totaled $33.0 million as of June 30, 2026, with $50 million from the private placement received in July 2026.

Outlook and guidance

• Cash and proceeds from the private placement expected to fund operations into Q2 2027, but substantial doubt remains about ability to continue as a going concern beyond 12 months without additional capital.

• Multiple clinical data milestones for MICVO expected in Fall and Q4 2026, including updated monotherapy and combination data.

• Ongoing need for additional funding anticipated due to continued operating losses and increased R&D expenses.